AMLX vs EQR · $561.6M cap vs P/E 26, $26.37B cap
Amylyx Pharmaceuticals Inc (AMLX) versus Equity Residential (EQR) — a side-by-side from cached financials, not a winner call.
Amylyx Pharmaceuticals Inc (AMLX) is a biotechnology company listed on US.
Equity Residential (EQR) is a reit - residential company listed on US.
Latest reported AMLX revenue for 2025-12-31 was $0. Net income was -$144.7M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. AMLX currently screens at market cap $561.6M.
EQR does not have a complete income-statement cache yet.
AMLX currently screens at market cap $561.6M. EQR currently screens at market cap $26.37B and trailing P/E 25.7.
Not investment advice. Open the AMLX and EQR stock pages for the full models.
Not investment advice.